SEARCH

SEARCH BY CITATION

References

  • 1
    Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 247 61
  • 2
    Birkhoff JD, Wiederhorn AR, Hamilton ML, Zinsser HH. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 1976; 7: 48 52
  • 3
    Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495 507
  • 4
    Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469 71
  • 5
    Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 1995; 332: 99 109
  • 6
    Simpson RJ, Fisher W, Lee AJ, Russell EB, Garraway M. Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol 1996; 77: 186 91
  • 7
    Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia; appropriate case definition and estimation of its prevalence in the community. Urology 1995; 46: 34 40
  • 8
    Britton JP, Dowell AC, Whelan P. Prevalence of urinary symptoms in men over 60. Br J Urol 1990; 66: 175 6
  • 9
    Drummond MF, McGuire AJ, Black NA, Petticrew M, McPherson CK. Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993; 71: 290 6
  • 10
    Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. The Prostate (Suppl) 1996; 6: 67 73
  • 11
    The EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199 208
  • 12
    Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2: 167 8
  • 13
    Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551 9
  • 14
    Barry MJ, Fowler Fj Jr, O’Leary MP et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992; 148: 1549 57
  • 15
    Barry MJ, Fowler FJ, O’Leary MP et al. Correlation of the American Urological Association Symptom Index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program Indexes. J Urol 1992; 148: 1558 63
  • 16
    Cockett AT & Aso Y et al. Recommendation of the International Consensus Committee on prostate symptom score and quality of life assessment. In Cockett ATK, Khoury S, Aso Y et al., Paris: Scientific Communication International Ltd, 1994; 553 5
  • 17
    Homma Y, Kawabe K, Tsukamoto T et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int J Urol 1997; 4: 40 6
  • 18
    Sagnier PP, Girman CJ, Garraway M et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15 20
  • 19
    Norman RW, Nickel JC, Fish D, Pickett SN. ‘Prostate-related symptoms’ in Canadian men 50 years of age or older; prevalence and relationships among symptoms. Br J Urol 1994; 74: 542 50
  • 20
    Bosch JLHR, Hop WCJ, Kirkels WJ, Schroeder FH. The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: prevalence and relationships among symptoms. Br J Urol 1994; 74: 542 50
  • 21
    Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85 9